-
Innovation Ranking
Innovation Ranking – TG Therapeutics Inc
TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and various autoimmune diseases. The company’s approved products in the US include Ukoniq for the treatment of relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma. The pipeline products of the company include TG-1701 and TG-1801 for the treatment of B-cell cancers and other diseases. The company also evaluates products and technologies for in-licensing, partnership,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-4050 in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Hypopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-4050 in Hypopharyngeal Cancer Drug Details: TG-4050 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-4050 in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Laryngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-4050 in Laryngeal Cancer Drug Details: TG-4050 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-4050 in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Oropharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-4050 in Oropharyngeal Cancer Drug Details: TG-4050 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-01 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-01 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-01 in Pancreatic Ductal Adenocarcinoma Drug Details: TG-01 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-1042 in Cutaneous B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-1042 in Cutaneous B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-1042 in Cutaneous B-Cell Lymphoma Drug Details: TG-1042 (ASN-002) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-4050 in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Oral Cavity (Mouth) Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-4050 in Oral Cavity (Mouth) Cancer Drug Details: TG-4050...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-01 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-01 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-01 in Non-Small Cell Lung Cancer Drug Details: TG-01...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-4050 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-4050 in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-1042 in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-1042 in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-1042 in Basal Cell Carcinoma (Basal Cell...